Patents by Inventor Paul Levi Miller
Paul Levi Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150203590Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.Type: ApplicationFiled: April 3, 2015Publication date: July 23, 2015Inventors: Paul Levi MILLER, Laura CORRAL
-
Patent number: 9000132Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.Type: GrantFiled: July 31, 2013Date of Patent: April 7, 2015Assignee: diaDexus, Inc.Inventors: Paul Levi Miller, Laura Corral
-
Publication number: 20140275485Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.Type: ApplicationFiled: July 31, 2013Publication date: September 18, 2014Applicant: diaDexus, Inc.Inventors: Paul Levi MILLER, Laura CORRAL
-
Publication number: 20140283157Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: diaDexus, Inc.Inventors: Paul Levi Miller, Laura Corral
-
Patent number: 8354508Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.Type: GrantFiled: July 20, 2007Date of Patent: January 15, 2013Assignee: Diadexus, Inc.Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
-
Patent number: 8030458Abstract: An IgG1? monoclonal antibody to the immunosuppressive drug tacrolimus has improved properties. In particular, this monoclonal antibody, designated 1H6, has reduced cross-reactivity to several tacrolimus metabolites. This antibody is suitable for performance of immunoassays such as homogeneous immunoassays to detect or determine the presence or concentration of tacrolimus in samples such as blood samples. The invention further includes derivatives of tacrolimus derivatized at a non-binding portion of the molecule useful in immunizing antibody-producing animals and in producing such monoclonal antibodies, as well as labeled derivatives of tacrolimus useful as tacrolimus analogues in such assays. The invention further includes immunoassay methods for the detection of tacrolimus and test kits useful in performing such immunoassays.Type: GrantFiled: September 26, 2008Date of Patent: October 4, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Kenneth Cornell Kasper, Henry Jeong, Dariush Davalian, Hshiou-ting Liu, Paul Levi Miller, Denise Leah Williams
-
Publication number: 20100150907Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.Type: ApplicationFiled: July 20, 2007Publication date: June 17, 2010Applicant: DIADEXUS, INC.Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
-
Publication number: 20100074893Abstract: The invention provides isolated anti-ECM-complex antibodies that bind to ECM-complexes. The invention also encompasses compositions comprising an anti-ECM-complex antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-ECM-complex antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-ECM-complex antibodies. The invention encompasses a method of producing the anti-ECM-complex antibodies. Other aspects of the invention are a method of detecting an ECM-complex expressing cancer, a method of inhibiting growth of an ECM-complex-expressing tumor, and a method of alleviating or treating an ECM-complex-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-ECM-complex antibody to the mammal.Type: ApplicationFiled: April 10, 2009Publication date: March 25, 2010Inventors: Annette Bistrup, Gundo Diedrich, Paul Levi Miller
-
Publication number: 20090087865Abstract: An IgG1? monoclonal antibody to the immunosuppressive drug tacrolimus has improved properties. In particular, this monoclonal antibody, designated 1H6, has reduced cross-reactivity to several tacrolimus metabolites. This antibody is suitable for performance of immunoassays such as homogeneous immunoassays to detect or determine the presence or concentration of tacrolimus in samples such as blood samples. The invention further includes derivatives of tacrolimus derivatized at a non-binding portion of the molecule useful in immunizing antibody-producing animals and in producing such monoclonal antibodies, as well as labeled derivatives of tacrolimus useful as tacrolimus analogues in such assays. The invention further includes immunoassay methods for the detection of tacrolimus and test kits useful in performing such immunoassays.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Kenneth Cornell Kasper, Henry Jeong, Dariush Davalian, Hshiou-ting Liu, Paul Levi Miller, Denise Leah Williams
-
Patent number: 7078495Abstract: An IgG1 ? monoclonal antibody to the immunosuppressive drug tacrolimus has improved properties. In particular, this monoclonal antibody, designated 1H6, has reduced cross-reactivity to several tacrolimus metabolites. This antibody is suitable for performance of immunoassays such as homogeneous immunoassays to detect or determine the presence or concentration of tacrolimus in samples such as blood samples. The invention further includes derivatives of tacrolimus derivatized at a non-binding portion of the molecule useful in immunizing antibody-producing animals and in producing such monoclonal antibodies, as well as labeled derivatives of tacrolimus useful as tacrolimus analogues in such assays. The invention further includes immunoassay methods for the detection of tacrolimus and test kits useful in performing such immunoassays.Type: GrantFiled: August 3, 1999Date of Patent: July 18, 2006Assignee: Dade Behring Inc.Inventors: Kenneth Cornell Kasper, Henry Jeong, Dariush Davalian, Hshiou-ting Liu, Paul Levi Miller, Denise Leah Williams